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E-mail address: jholo@umich.edu (J. Holoshitz).The shared epitope (SE) – an HLA-DRB1-encoded 5-amino acid sequence motif carried by the vast
majority of rheumatoid arthritis (RA) patients – is a risk factor for severe disease. The mechanistic
basis of RA-SE association is unknown. This group has previously demonstrated that the SE acts as a
signal transduction ligand that activates nitric oxide and reactive oxygen species production. SE-
activated signaling depends on cell surface calreticulin, a known innate immunity receptor previ-
ously implicated in immune regulation, autoimmunity and angiogenesis. Recent evidence that
the SE enhances the polarization of Th17 cells, which is a key mechanism in autoimmunity, is dis-
cussed highlighting one of several potential functional effects of the SE in RA.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Rheumatoid arthritis (RA) affects 0.5–1.0% of the population [1].
The disease is characterized by chronic inflammatory changes in
both articular and extra-articular tissues. Due to its high preva-
lence and debilitating nature, RA inflicts a major economic burden
on society. In recent years it has been realized that in addition to
causing pain and disability, the disease significantly shortens life
expectancy due to accelerated atherosclerosis [2].
Although genes play a major role in RA risk, the disease appears
to have low sibling occurrence with a concordance rate of 12–15%
in monozygotic twins [3]. Overall, the contribution of genetic fac-
tors to RA risk is calculated at approximately 60%, while the
remaining 40% are believed to be contributed by environmental
factors. The observations that RA is more common in urban versus
rural populations, a recent decline in the incidence of the disease
in high-incidence of populations, and the effect of birth cohort
on disease incidence are all indirectly supporting environmental
influences. Importantly, over the past few years it has been conclu-
sively shown that the disease is strongly associated with environ-
mental pollutants, such as cigarette smoking [4].
Among the genetic risk factors, the HLA-DRB1 locus is the most
significant one. RA has long been shown to associate with humanchemical Societies. Published by E
ichigan School of Medicine,
or, MI 48109-5680, USA. Fax:leukocyte antigen (HLA) genes. The pioneering studies on HLA-
RA association were carried out in the late 1970s by Peter Stastny
[5] and Robert Winchester’s group [6], who independently con-
cluded that HLA-DR4 is significantly more common among pa-
tients with RA. It was subsequently found that other HLA-DR
serotypes, for example, HLA-DR1 in Mediterranean, or HLA-DR14
in Native Americans, are also associated with the disease. With
the advent of modern DNA sequencing techniques it had become
apparent in the 1980’s that there is no RA-specific HLA-DR
sequence. Instead, it was found that the majority of RA patients
share a short sequence motif coded by several HLA-DRB1 alleles.
This revelation had prompted the Shared Epitope Hypothesis [7].2. The RA shared epitope
The term ‘‘shared epitope’’ (SE) most commonly refers to a five
amino acid sequence motif in residues 70–74 of the DRb chain
coded by several HLA-DRB1 alleles that are over-represented
among RA patients (Fig. 1). The SE motif consists of three homolo-
gous amino acid sequence variants: (1) QKRAA, the SE variant that
is the most common motif among Caucasian, is coded primarily by
the HLA-DRB1⁄0401 allele; (2) The second most common motif,
QRRAA, is coded by several alleles, among them HLA-DRB1⁄0404,
HLA-DRB1⁄0101, and HLA-DRB1⁄0405; (3) The third motif, RRRAA,
coded by allele HLA-DRB1⁄1001, is the rarest. In addition to
increasing RA risk, SE-coding HLA-DRB1 alleles have been shown
to associate with more severe disease [8] and to exhibit allele-doselsevier B.V. All rights reserved.
Fig. 1. Structure and epidemiology of the RA SE. (A) ‘Top’ view of a SE-expressing (HLA-DR1) molecule. The a chain is shown in green, the b chain is in yellow and the groove
peptide is in brown. The red arrow points at the SE-containing a helical loop. (B) ‘Side’ view of the same molecule. Note the localization of the SE near the b chain ‘kink’. (C)
Ethnic and geographic distribution of RA-associated HLA-DRB1 alleles and their SE products.
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more severe disease than patients with 1 allele, who, in turn, have
more severe RA than SE-negative patients.
The mechanism underlying the effect of the SE is unclear. Based
on the known role of MHC class II molecules in antigen presenta-
tion, the prevailing paradigms postulate that presentation of
arthritogenic self-peptides [9], molecular mimicry with foreign
antigens [10], or T cell repertoire selection [11] are involved. While
these hypotheses are all plausible, they are difficult to reconcile
with the fact that data supporting antigen-specific responses as
the primary event in RA are inconclusive. Additionally, several
other human diseases have also been shown to be associated with
SE-encoding DRB1 alleles, including polymyalgia rheumatica [12],
giant cell arteritis [12], Type I diabetes [13], erosive bone changes
in psoriatic arthritis [14] and lupus [15], autoimmune hepatitis
[16] and early-onset chronic lymphoid leukemia [17], among other
conditions. The SE is also associated with spontaneous arthritis in
dogs [18] and, in HLA-DRB1⁄0401 transgenic mice it increases the
incidence of spontaneous diabetes [19] and the severity of both
collagen-induced arthritis (CIA) [20] and experimental autoim-
mune encephalomyelitis (EAE) [21]. Thus, although it is best
known for its involvement in RA, the SE associates with several
pathogenically unrelated diseases and experimental disease mod-
els, and its effect seems to lack antigen- or species-specificity.
These promiscuities are incongruent with fundamental tenets of
MHC-restricted antigen presentation theory.3. Activation of innate signaling by the SE: a new paradigm
Given the inconsistencies of SE-RA association with antigen pre-
sentation-based theories, over the past few years, our laboratory
has examined an alternative hypothesis concerning the role of
the SE in RA [22–28]. Based the known tri-dimensional homology
among products of the MHC gene family, we postulated that sim-
ilar to class I MHC-coded molecules [29], the SE may be acting as a
ligand that can trigger innate immune signaling. The rationale of
this antithetic hypothesis relates to the fact that the SE is locatednear the apex of a helical tri-dimensional structural motif that
has been preserved throughout the entire MHC gene family and
seems to be enriched in signal transduction ligands.
The first crystal structure of a class II MHC molecule, published
in 1993 by Don Wiley’s group [30], revealed a remarkable tri-
dimensional similarity to a previously reported class I MHC mole-
cule. The degree of the similarity was surprising, given a substan-
tial evolutionary distance between the two molecules and the fact
that the peptide-binding groove in class I molecules is coded by a
single gene, while in class II it is formed jointly by the products of
two distinct genes. The extent of evolutionary ‘choreography’ re-
quired to bring these two disparate MHC molecules to form a
near-identical tri-dimensional structure, is staggering. One of the
notable features of the similarity is a ‘kink’ in the a2 domain of
the class I MHC molecule, which could be almost perfectly super-
imposed on a similar structure in the b1 domain of the class II mol-
ecule. The ‘kink’ region in both molecules involves allele-diversity
regions. Subsequent crystal analyses have shown very similar tridi-
mensional structures in the entire MHC gene product family, irre-
spective of whether or not they can present antigens [31]. In all
cases, this region forms a sharp protrusion ‘above’ the MHC groove
plane (Fig. 1).
The remarkable conservation of a similarly-shaped ‘kink’ in the
midst of allele diversity regions in MHC molecules independent of
their antigen presentation capabilities suggests that this region
may possess important allele-specific, conformationally-depen-
dent, non-antigen presentation functions. Indeed, there are some
indications that this region performs such functions. For example,
in both classical and non-classical (HLA-E) class I MHC molecules,
this region contains ligands for natural killer (NK) cell receptors
[32]; in HFE (an empty-grooved human class I-like molecule), it
interacts with transferrin receptor [33]; In M10 (a mouse class I-
like molecule), the same region has been proposed as an interac-
tion site with a pheromone receptor [34].
These considerations have led us to pursue a novel hypothesis
which postulates that similar to its structural homologue in the
class I MHC molecule, the SE functions as a signal transduction li-
gand that interacts with an evolutionarily-conserved receptor. Our
Fig. 2. The SE-CRT pathway. See text for details. Abbreviations: cAMP, cyclic AMP;
cGMP, cyclic GMP; GPCR, G protein-coupled receptor; Gs, stimulatory G protein;
NOS, NO synthase.
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expressed in its native conformation on the cell surface; as a
cell-free HLA-DR tetrameric molecule; engineered into large re-
combinant proteins; or as a short synthetic peptide, activated in
all cases nitric oxide (NO)-mediated signaling in trans in a strictly
allele-specific manner. A consensus motif comprising of the 70Q/
R-K/R-x-x-A74 sequence was found to be necessary for triggering
the signal.
Given the known pro-oxidative effect of NO and the proposed
role of oxidative stress in the pathogenesis of RA, we have explored
whether SE-triggered signaling can increase cellular oxidative
stress. These studies have shown that cells exposed to cell surface
SE-positive HLA-DR molecules, to cell-free recombinant proteins
genetically engineered to express the SE motif, or to SE-positive
synthetic peptide showed diminished cyclic AMP-dependent sig-
naling, increased reactive oxygen species (ROS) levels, and higher
vulnerability to oxidative DNA damage. The SE effect is critically
dependent on amino acids Q/R70, K/R71 and A74 of the DRb chain.
The pro-oxidative effect of the SE could be reversed by inhibiting
NO production. Thus, these studies demonstrate that the SE acts
as a signaling ligand that activates an NO-mediated pro-oxidative
pathway.
SE-triggered signaling is transduced via cell surface calreticulin
(CRT), a known innate immunity receptor. The role of CRT and the
dependence on CD91 have been published [25]. In brief, cell sur-
face CRT was identified as the SE-binding molecule using affinity
chromatography purification, cell-binding assays, surface plasmon
resonance (SPR) and time-resolved fluorescence resonance energy
transfer techniques. SE-triggered signaling could be blocked by
anti-CRT antibodies or antibodies against CD91 and by CRT-specific
anti-sense or small interfering RNA (siRNA) oligonucleotides. Mur-
ine embryonic fibroblasts from Crt/ or cd91-deficient mice failed
to transduce SE-activated signals. Exogenously added soluble CRT
attached to the cell surface and restored signaling responsiveness
in Crt/ cells.
More recently we have mapped the SE binding site on CRT [28].
SPR experiments with domain deletion mutants suggested that the
SE binding site is located in the P-domain of CRT. The role of this
domain as a SE-binding region was further confirmed by a photo-
active cross-linking and mass spectrometry methods. In silico anal-
ysis of docking interactions between a conformationally intact SE
ligand and the CRT P-domain predicted the region within amino
acid residues 217–224 as a potential SE binding site. Site-directed
mutagenesis demonstrated involvement of residues Glu217 and
Glu223 and, to a lesser extent, residue Asp220 in cell-free SPR-based
binding and signal transduction assays.4. Potential functional consequences of SE-activated signaling
As illustrated in Fig. 2, the SE acts as a signal transduction ligand
that interacts with cell surface CRT and activates signal transduc-
tion in trans. Although the SE-CRT pathway has not been fully
mapped, our data to date indicate that it involves activation of
NO synthase, and production of ROS. We have also demonstrated
that the SE-activated pathway blocks a cyclic AMP-mediated path-
way [23].
NO is a ubiquitous signaling molecule with versatile effects in
the immune system. In RA, increased NO levels correlate signifi-
cantly with inflammatory markers [35] and anti-rheumatic agents
have been shown to suppress NO production [35,36]. NO has also
been implicated in the pathogenesis of experimental autoimmune
models in mice. For example, SJL mice (H-2s) are known for their
NO overproduction [37]. These mice are susceptible to many auto-
immune diseases, including EAE, myasthenia, myositis, inflamma-
tory bowel disease and CIA [38], and their autoimmune tendenciesare attributed to their NO overproduction [39]. Similar to human
RA, SJL mice display aging-associated increase in disease incidence
[40], excessive DNA damage [41], higher mutation rates [42] and
higher incidence of spontaneous lymphoma [43].
There are many ways by which NO could contribute to RA path-
ogenesis. The salient cellular mechanisms by which SE-activated
NO could be involved in RA are depicted in Fig. 3. For example:
 NO has been shown to modulate apoptosis, a process that has
been extensively implicated in RA and other autoimmune con-
ditions [44].
 NO plays a major role in angiogenesis [45], a key pathogenic
mechanism in the inflammatory pannus. Blood vessels are crit-
ically important for both nourishing the proliferative synovial
tissue and for the ingress of inflammatory leukocytes into the
joint. Anti-angiogenic agents have been shown to modulate
arthritis in animal models of RA [46]. Additionally, certain dis-
ease modifying anti-rheumatic drugs, such as methotrexate or
anti-TNFa antibodies, have been found to be angiostatic [47].
Thus, SE-activated NO overproduction could conceivably
enhance angiogenesis in RA.
 The pathogenesis of RA pannus involves activation of matrix
metalloproteinases (MMPs), with MMP-13 being of particular
interest. The relevance of this MMP to RA relates to its high
potency and specificity for type II collagen [48]. In addition to
its direct tissue degrading effects, MMP-13 is a likely contribu-
tor to RA pathogenesis due to its central position in the MMP
activation cascade [49] and its pro-angiogenic effect [50].
MMP-13 is upregulated by inflammatory cytokines, such as
IL-1, IL-6, TNFa and IL-17 [51]. Consistent with the model dis-
cussed here, NO has been shown to increase MMP-13 expres-
sion and activity [52].
 Directly relevant to the focus of this review, NO has been
recently shown to potently inhibit indoleamine 2,3 dioxygenase
(IDO), a tolerogenic enzyme [53,54]. Our recent studies have
indeed demonstrated that the SE, which trigger NO signaling
in dendritic cells (DCs) has an inhibitory effect on IDO activa-
tion, with immune dysregulatory effect, both in vitro and
in vivo (see below).
Fig. 3. Potential RA-relevant functional consequences of SE-activated signaling.
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stress. The role of ROS in RA has been extensively studied [55].
There are many potential RA-relevant cellular and molecular
mechanisms that could be affected by excessive production of
ROS. Among them: protein and DNA damage, epigenetic modifica-
tions, telomere attrition, cell senescence and T cell hyporespon-
siveness, all of which have been implicated in the pathogenesis
of RA [56–61]. Among the many potential pathogenic effects, two
ROS-mediated disease processes are of particular interest: athero-
sclerosis (AS) and bone erosions.
As mentioned above, RA patients have long been noticed to
have shorter life expectancy. It is now becoming increasingly
apparent that AS is the most common cause of premature death
in RA with a relative risk of about 2, compared with age-matched
control populations [2]. Several studies have noted the fact that
AS risk in RA exists in a rate greater than would be expected from
the profile of classical cardiovascular risk factors, such as diabetes
mellitus, hypercholesterolemia, obesity or hypertension [62]. The
prevalent hypothesis for the increased risk of AS in RA attributes
the association to inflammation. However, there is substantial evi-
dence to suggest that the inflammatory milieu may not be the sole
culprit. For example, in RA patients without established cardiovas-
cular risk factors, the erythrocyte sedimentation rate was found to
lack correlation with the carotid intima-media thickness, a known
biomarker of AS [63]. Additionally, in RA patients chronically trea-
ted with TNFa blockers, endothelial cell dysfunction continues to
exist [64] and AS continues to progress [65] despite reversal of
the inflammatory state and improvement of the arthritis. Finally,
patients with many other inflammatory conditions are not known
to be at a higher AS risk, suggesting that disease-specific factors
may contribute to the increased AS risk in RA. Given the unequiv-
ocal role of oxidative stress in AS on one hand, and anecdotal re-
ports suggesting that SE association with AS may exist also in the
non-RA population [66–68] on the other, the possibility that SE-
activated ROS production might be a direct contributing factor to
premature AS development in RA is worth consideration.
Osteoclast-driven destruction of juxta-articular bone is a hall-
mark of RA. The severity of bone destruction is RA has been linked
to the SE [69] with indications for allele-dose effect in certain pop-
ulations [70]. Interestingly, the SE has also been implicated in ero-
sive changes in non-RA conditions, such as psoriatic arthritis [14],
SLE [15] and periodontal disease [71]. Thus, the SE may be involved
in bone destruction irrespective of the underlying disease. Themechanism discussed here involving SE-activated NO and ROS pro-
duction might provide a mechanistic basis for these associations. It
has been previously shown that NO activates osteoclasts in a bi-
phasic dose-dependent fashion [72]. ROS, likewise, have been
shown to activate osteoclastogenesis [73] and bone resorption
[74]. Accordingly, one scenario to consider is that the SE may con-
tribute to osteoclast activation by stimulating higher production of
NO and ROS, thereby increasing osteoclast-mediated bone
destruction.
5. A case in point: SE-activated immune dysregulation
Using the diagram shown in Fig. 3 as a ‘blueprint’, this labora-
tory has been investigating RA-relevant SE effects in several path-
ogenic system with encouraging results. Here we discuss our
recent findings in one of the areas of our current research interest:
SE-activated immune dysregulation.
As discussed in greater detail in a recent review [27] CRT has
been previously implicated in immune regulation. CRT is a
60 kDa protein which is expressed on the surface of many cells
[75,76] and functions as an important innate immune system
receptor [77–79]. It serves as the signal-transducing receptor for
members of the collectin family [80]. Collectins bind foreign organ-
isms or apoptotic cells through their globular heads, while their
collagen-like tails bind to cell surface CRT. This leads to CRT-
dependent phagocytosis. Different from elimination of foreign
organisms, events which are associated with an intense inflamma-
tory reaction [81], safe elimination of apoptotic cells is critically
dependent on suppressing the inflammatory response [82]. The
decision whether a pro- or anti-inflammatory reaction should be
activated depends on the presence or absence of second signals
that are triggered uniquely by apoptotic cells [83]. Thus, CRT plays
a pivotal role in the junction between tolerance and autoimmunity
due to its critical role in elimination of apoptotic cells [80].
Aberrant activation of the CRT-mediated pathway can lead to
autoimmunity as exemplified by conditions that involve defective
CRT-mediated clearance of apoptotic cells [84].
Our research interest in the effect of the SE on DCs is partly
based on the fact that these cells are known to express functional
CRT receptors on their surface [76]. DCs are professional antigen
presenting cells strategically positioned in the interface between
the innate and adaptive immune systems. In addition to their role
in antigen presentation, DCs also induce tolerance through a vari-
D.E. de Almeida et al. / FEBS Letters 585 (2011) 3619–3626 3623ety of mechanisms, including a direct cross talk with regulatory T
(Treg) cells [85]. A growing body of evidence indicates that the
tolerogenic effect of DCs is mediated partly by IDO, an enzyme that
catalyzes the catabolism of tryptophan [86,87]. The precise mech-
anism by which IDO exerts its effect is unknown, but may involve
tryptophan depletion and/or pro-apoptotic or anti-proliferative ef-
fects of tryptophan downstream metabolites [88]. IDO is inducible
in DCs by the Th1 cytokine IFNc [89] and by Treg-expressed CTLA4
through ligation of cell surface CD80/CD86 molecules [90]. Activa-
tion of IDO in DCs by Treg has been shown to inhibit IL17-produc-
ing helper T (Th17) cells [91], a T cell subset that is believed to play
a key role in autoimmunity (discussed below).
It is worth noting that in contrast to the IDO-inducing effect of
IFNc and CTLA4, NO is a potent inhibitor of IDO [53,54]. Given our
findings that the SE activates NO production in many cell types,
including DCs, we examined whether the SE ligand could affect
IDO enzymatic activity. Using murine fibroblast L-cells transfec-
tants expressing structurally intact and functionally HLA-DRa/b
heterodimeric molecules through cDNA transfection we demon-
strated that transfectants expressing SE-positive HLA-DR mole-
cules on their surface produced significantly less kynurenine (an
IDO-dependent tryptophan metabolite) in response to IFNc, com-
pared to transfectants expressing SE-negative HLA-DR molecules.
An identical pattern was seen when human fibroblasts were stim-
ulated with a soluble SE ligand in the form of SE-expressing pep-
tides. Importantly, the SE ligand IDO inhibitory activity was
restricted to CD11c+CD8+ DCs, a subset known to express IDO
[92]. Thus, the SE ligand effectively and specifically inhibits the
activity of the tolerogenic enzyme IDO in DCs.
In addition to IDO-mediated T cell regulation, DCs can affect im-
mune reactions by production of cytokines that can activate or ex-
pand particular subsets of T cells. In mice, the combination of IL-6
and TGFb facilitates differentiation of Th17 cells, while IL-23 is in-
volved in the expansion of this subset [93]. Accordingly, we have
studied supernatants of SE-stimulated DCs. Our data showed that
in the CD11c+CD8- DC subset, but not in the CD11c+CD8+ subset,
a SE peptidic ligand activated a robust production of IL-6. An SE-
negative ligand did not trigger any cytokine production. Other
cytokines (IL-4, IL-10, IL-12, IL-1b, TGFb) did not show any in-
creased production, indicating the specificity of SE effect. Interest-
ingly, IL-23 levels in DCs did not increase following stimulation
with the SE ligand. However, in the presence of suboptimal con-
centrations of LPS (100 ng/ml), the SE had a prolonged synergistic
effect on IL-23 production. The effect was specific for IL-23, since
no synergism was found in the production of another LPS-induc-
ible cytokine, IL-6.
It has been previously demonstrated that IDO inhibition [94] or
increased IL-6 levels [95] inhibit Treg cells. As discussed above, the
SE inhibited IDO activity in CD11c+CD8+ DCs and increased IL-6
production in CD11c+CD8 DCs. We therefore determined whether
the SE interferes with Treg differentiation. Mouse CD11c+DCs were
first incubated overnight with SE-positive or SE-negative peptides,
or with medium. DCs were then co-cultured with purified synge-
neic CD4+ T cells or CD4+CD25CD62L+CD44 naïve T cells in the
presence of TGF-b and anti-CD3 Ab. After 5 days, CD4+CD25+Foxp3+
Treg abundance was determined by FACS analysis. Our data
showed that the SE-positive, but not an SE-negative ligand, signif-
icantly inhibited Treg cell differentiation. Similarly, splenic
CD4+CD25CD62L+CD44 naïve T cells cultured with CD11c+DCs,
treated with a SE-positive HLA-DR tetramer, but not with SE-neg-
ative HLA-DR tetramers demonstrated markedly reduced Treg cell
differentiation.
Since SE ligands were found to enhance production of Th17-
promoting cytokines, IL-6 and IL-23, we determined whether they
can facilitate Th17 differentiation. To this end, CD11c+DCs were
first stimulated overnight with SE-expressing peptides or tetra-mers. CD4+CD25CD62L+CD44 naïve T cells were added and cul-
tured in the presence of a Th17-polarizing cocktail of cytokines
and antibodies. After 6 days cells were collected and analyzed by
flow cytometry. The results showed that SE-positive ligands, in
particular when presented as HLA-DR tetramers, had a robust
enhancement of Th17 differentiation. The SE showed similar effect
when expansion of Th17 cells was studied [26].
To determine the biologic significance of the in vitro data shown
above, we have undertaken to characterize the SE polarizing effect
in vivo. Our findings showed that mice immunized with collagen
type II in the presence of a cell-free SE ligand displayed much high-
er abundance of Th17 cells in the draining lymph nodes, compared
to mice immunized with the same antigen in the presence or ab-
sence of a control ligand. Similarly, splenocytes from mice immu-
nized with collagen in the presence of the SE ligand produced
much higher levels of IL-17 compared to the control groups [26].
Thus, the SE facilitates Th17 polarization both in vitro and in vivo.
It is worth noting that IL-17 has been shown to enhance several
pro-arthritogenic processes, including angiogenesis, MMPs produc-
tion, osteoclastogenesis, leukocyte recruitment and inflammation
[96]. Both IL-17-producing cells and IL-17 are abundantly expressed
in the RA joint [97], and neutralizing IL-17 prevents experimental
arthritis development,while deficiency of Treg cells has been shown
to increase cellular and humoral immune responses and disease
severity in CIA [98]. Thus, SE-activated Th17 polarization, observed
by us both in vitro and in vivo, suggests a potential mechanism by
which the SE could affect RA pathogenesis.
6. A proposed model
Different from the prevailing paradigms, which attribute the
role of the SE in RA to presentation of a putative self or foreign anti-
gen, the considerations discussed above and our experimental
findings implicate an allele-specific, antigen presentation-indepen-
dent mechanism. We have shown that the SE activates RA-relevant
signaling events in several immune and non-immune cell types.
The SE signaling effect is independent of the antigen presentation
function of the parent HLA-DR molecule and could be seen using
synthetic SE ligands, which do not possess any antigen presenta-
tion capability. It is worth mentioning, however, that using X-ray
crystallography-based analyses others have predicted that amino
acid residues K71 [99], or Q70 and K71 [100] of the HLA-
DRB1⁄0401-coded SE may participate in the binding to human col-
lagen type II-derived groove peptides. These predictions seemingly
conflict with the model proposed here, however, it should be ex-
plained that: (1) The identity of the target antigen in RA is un-
known. The role of collagen type II as a target self antigen has
been disputed by many. It is therefore unclear whether the pro-
posed interactions between SE residues and collagen II epitopes
are pathogenically relevant; (2) Different groove peptides may
have different affinities to the SE. It is therefore conceivable that
CRT could displace certain types of peptides; (3) Another scenario
to consider is that CRT interacts primarily with ‘empty’-grooved
HLA-DR molecules; (4) Our preliminary data using SE-positive
HLA-DR tetrameric molecules loaded with two distinct groove pep-
tides suggest that the identity of the peptide does not have any sig-
nificant impact on SE-CRT interaction or signaling (unpublished
results); (5) Finally, as discussed bellow, the antigen presentation
paradigm and the SE signaling hypothesis are not mutually exclu-
sive. We cannot rule out a scenario in which certain groove pep-
tides and CRT could co-interact with the SE.
Based on the experimental and theoretical considerations dis-
cussed above, we propose the followingmodel: In healthy individu-
als carrying SE-codingHLA-DRB1 alleles, the SE ligand, expressed on
antigen presenting cells or lymphocytes interacts at low affinity
with cell surface CRT. As our data show, SE activation of DCs pro-
Fig. 4. A proposed model. The SE ligand, expressed on antigen presenting cells or lymphocytes interacts with cell surface CRT. In DCs this interaction promotes Th17
polarization, which in healthy individuals could be advantageous against pathogens. In RA, due to environmentally-triggered non-genetic changes, the affinity of SE-CRT
interaction could increase with resultant aberrant activation of the SE pathway, excessive Th17 polarization and disease development. IL-17 has been previously shown to
promote autoimmunity through its effect on many target tissues. In addition to its Th17 polarizing effect through activation of DCs, the SE could conceivably directly activate
functional consequences in other cell systems (shown in italics) known to contribute to RA pathogenesis.
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advantageous against pathogens.We further propose that over time,
due to environmentally-triggered stochastic events, the affinity of
SE-CRT interaction could increasewith resultant aberrant activation
of the SE pathway, excessive Th17 polarization and development of
RA. It is worthmentioning here that different fromhumans,mice do
not express class IIMHCmolecules on the surface of activatedT cells.
We therefore posit that the reported SE-promoted autoimmunity in
HLA-DRB1 transgenic mice could be due to activation of pro-inflam-
matory signaling by SE expressed on cells other than T lymphocytes
(i.e., macrophages, B lymphocytes or DCs).
This model is non-exclusive with other hypotheses in the field.
One scenario to consider is that while SE-expressing HLA-DR mol-
ecules are uniquely capable of presenting joint-specific antigens,
thereby determining the tissue-specificity of the immune response
and its anatomical distribution, it is the SE ligand function that
determines the outcome of this response by facilitating Th17
polarization. Finally, we wish to clarify that given the focus of this
review on Th17, the simplified model proposed here highlights the
SE effect on DCs. However, the SE could conceivably activate RA-
associated functional consequences in other cell systems (some
of which are listed in Fig. 4).
7. Summary
We have previously demonstrated that the SE acts as a signal
transduction ligand that activates NO and ROS production in other
cells. SE signaling is transduced by cell surface CRT, a known innate
immunity receptor previously implicated in immune regulation,
autoimmunity and angiogenesis. There are multiple RA-relevant
cellular and molecular mechanisms that could conveivably exert
pathogenic influences secondary to activation of the newly discov-
ered pathway. An example of SE-activated aberrant immune regu-
lation that involves inhibition of the tolerogenic enzyme IDO on
one hand and enhanced Th17 expansion on the other is presented
here for illustration. Other conceivable SE-activated pathogenic
mechanisms are being currently studied by this group.Acknowledgements
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